In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. Article uri icon



  • The recent clinical success of cancer immunotherapy with checkpoint blockade has led to renewed interest into the development of immune modulatory agents with the capacity to activate anti-tumor T cell responses. Standardization of optimized in vitro assays for efficient assessment of immune function of such new drugs is thus needed to facilitate clinical development of the optimal drug candidates. Here, we describe an optimized version of T cell suppression assay designed to test the effect of immunomodulatory agents on T cell function and activation. We apply this assay to investigate the agonist activity of the T cell co-stimulatory molecule glucocorticoid-induced TNFR-related protein (GITR). We detail a protocol for concurrent assessment of multiple levels of T cell functional modulation upon GITR engagement, including T cell priming, activation and effector function, in a single assay. As human GITR agonist antibodies are currently under development, availability of standardized cell-based functional assays of GITR agonism is instrumental to translate anti-GITR therapy into the clinical setting.

publication date

  • October 22, 2019



  • Glucocorticoid-Induced TNFR-Related Protein
  • Immunologic Techniques
  • Immunomodulation
  • Lymphocyte Activation
  • T-Lymphocytes


PubMed Central ID

  • PMC7362725

Scopus Document Identifier

  • 85074394790

Digital Object Identifier (DOI)

  • 10.1016/bs.mie.2019.08.012

PubMed ID

  • 31948562

Additional Document Info


  • 631